Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for Juvéderm VOLUMA with Lidocaine, expanding its indications to include nose augmentation procedures.
Product Description and Benefits
Juvéderm VOLUMA with Lidocaine is a cross-linked sodium hyaluronate gel designed for injection into the upper periosteum of the nasal dorsum, columella, and anterior nasal spine. This treatment is intended to enhance the volume and shape of the external nose, providing a non-surgical option for patients seeking to improve their nasal contours. The inclusion of lidocaine in the formula helps to mitigate pain during the treatment process, enhancing patient comfort.
Historical Approval and Clinical Performance
Initially approved in China in November 2021 for deep cheek injection to reshape facial volume, Juvéderm VOLUMA with Lidocaine has demonstrated its ability to support and shape facial features. Clinical data from international studies indicate that the effects of the treatment can last up to two years, offering a long-lasting solution for patients.-Fineline Info & Tech
